BioHarvest Sciences Inc. (BHST)
| Market Cap | 87.50M -23.5% |
| Revenue (ttm) | 35.16M +26.9% |
| Net Income | -11.44M |
| EPS | -0.58 |
| Shares Out | 22.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,426 |
| Open | 3.810 |
| Previous Close | 3.900 |
| Day's Range | 3.810 - 3.940 |
| 52-Week Range | 3.570 - 12.800 |
| Beta | 1.37 |
| Analysts | Strong Buy |
| Price Target | 12.75 (+230.31%) |
| Earnings Date | May 14, 2026 |
About BHST
BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States. It operates through two segments: Products and CDMO Services. The company develops botanical synthesis platform technology to produce plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, marketing, and sale of science-based health and wellness nutraceutical solutions that are manufactured and sold as dietary supplements and functional food and beverages, as well as the manufacturing, ... [Read more]
Financial Performance
In 2025, BioHarvest Sciences's revenue was $34.51 million, an increase of 37.00% compared to the previous year's $25.19 million. Losses were -$11.14 million, -13.77% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for BHST stock is "Strong Buy." The 12-month stock price target is $12.75, which is an increase of 230.31% from the latest price.
News
Tate & Lyle Expands Collaboration with BioHarvest Sciences to Accelerate Next-Generation Sweetener Innovation
Expanded sweetener molecule development program aims to broaden access to plant-based sweetening solutions tailored to diverse customer food and beverage categories. Vancouver, British Columbia and Re...
BioHarvest Sciences Q1 Earnings Call Highlights
BioHarvest Sciences NASDAQ: BHST reported higher first-quarter revenue and reiterated its 2026 outlook as management detailed a broader reorganization around two business lines: its direct-to-consumer...
BioHarvest Sciences Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 8% year-over-year to $8.5M, with gross margin up to 59% and net loss at $2.6M. D2C and CDMO segments advanced, including a $1.2M fragrance contract and strong VINIA product adoption. Guidance for 2026 remains unchanged, with growth expected in H2.
BioHarvest Sciences Earnings release: Q1 2026
BioHarvest Sciences released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
BioHarvest Sciences Earnings release: Q1 2026
BioHarvest Sciences released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
BioHarvest Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
Quarterly revenue up 8% year over year; Annual revenue guidance range remains at $42-$48 million CDMO fragrance and Saffron projects reach successful milestones; First quarter CDMO revenue grew 135% Y...
BioHarvest Sciences Appoints New Head of Business Development for its CDMO Division
Business development appointment is aligned with securing long-term customers for development and manufacturing partnerships Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 13, ...
BioHarvest Sciences Announces Successful Completion of Stage 1 Development of Saffron Composition for Nutraceutical and Culinary Applications
- CDMO program advances to Stage 2 of development agreement valued at $1.125 million -Advancement of sustainable solution for the production of saffron, one of the world's most valuable and health-pro...
BioHarvest Sciences Signs $1.2M CDMO Stage 2 Contract for the Development of a Rare Fragrance Using Its Proprietary Botanical Synthesis Platform
Source plant is widely regarded as one of the most valuable fragrance raw materials in the world Stage 2 contract follows successful Stage 1 completion in March 2026 Vancouver, British Columbia and Re...
BioHarvest Sciences Slides: Corporate presentation
BioHarvest Sciences has posted slides in relation to its latest quarterly earnings report, which was published on May 1, 2026.
BioHarvest Sciences to Report First Quarter 2026 Financial Results on May 14, 2026
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - April 30, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its propr...
BioHarvest Sciences Announces Strategic Leadership Transition with Dr. Zaki Rakib Assuming Role of Chief Executive Officer to Accelerate "Two-Lens" Growth Strategy
Ilan Sobel joins Board of Directors with focused mandate on D2C growth. Dr. Zaki Rakib, Co-Founder and Executive Chairman, assumes role of Chief Executive Officer, Integrating R&D, Manufacturing, and ...
BioHarvest Sciences Slides: Corporate presentation
BioHarvest Sciences has posted slides in relation to its latest quarterly earnings report, which was published on April 1, 2026.
BioHarvest Sciences Earnings Call Transcript: Q4 2025
Q4 and full-year revenues grew 25% and 37% year-over-year, with gross margins improving to 58–59%. The D2C business, led by VINIA, achieved US category leadership, while the CDMO division advanced four major programs and expects to double or triple revenue in 2026.
BioHarvest Sciences Earnings release: Q4 2025
BioHarvest Sciences released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
BioHarvest Sciences Annual report: Q4 2025
BioHarvest Sciences has published its Q4 2025 annual report on March 31, 2026.
BioHarvest Sciences Reports Fourth Quarter and Full-Year 2025 Financial Results
FY2025 Revenues were $34.5 million, up 37% vs previous year. The VINIA brand has achieved the No.1 resveratrol polyphenol position in the United States Market*.
BioHarvest Sciences Announces First-Ever Successful Stable Cell Culture Development of Rare Fragrance-Producing Plant Using Proprietary Botanical Synthesis Platform
CDMO division has successfully completed Stage 1 under a development contract Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 31, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHS...
BioHarvest Sciences Announces that VINIA is Now the No.1 Resveratrol Polyphenol Brand in the United States
VINIA's leadership position in the market validates its superior arterial dilation and blood flow performance as well as BioHarvest's Botanical Synthesis platform technology Vancouver, British Columbi...
BioHarvest Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 17, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its propr...
BioHarvest Sciences Announces Grant of Long-Term Incentive Awards to Employees, Officers and Directors
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 13, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a company pioneering its patented Botanica...
BioHarvest Sciences Announces Board Transition and Appointment of Prof. Hezi Levy
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 5, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology,...
BioHarvest Sciences to Participate in 38th Annual Roth Conference on March 22-24, 2026
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 3, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical...
BioHarvest Sciences initiated with a Buy at Roth Capital
Roth Capital analyst Sean McGowan initiated coverage of BioHarvest Sciences (BHST) with a Buy rating and $10 price target The firm believes the company’s botanical synthesis platform will drive “signi...
BioHarvest Sciences Issues Year End Shareholder Letter
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - January 7, 2026) - BioHarvest Sciences Inc. , (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its pa...